Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Suppl. Figure 3: Total number of drug injections administered at home

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Suppl. Figure 4: Empirical distribution of the total cost

HaH: Hospital care at Home
OH: Outpatient Hospital

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Suppl. Figure 5: Distribution of total cost OH/ HaH vs OH

HaH: Hospital care at Home OH: Outpatient Hospital

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Suppl. Figure 6: Health cost (medication, transport and drug administration) distribution

HaH: Hospital care at Home OH: Outpatient Hospital

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Suppl. Table 2: Patient characteristics

	Total Population n = 54	
Age (years)	Disease Diagnosis Age	1st HaH	
<50	7 (14%)	4 (7,5 %)	
50-70	26 (51%)	26 (48 %)	
>70	18 (35 %)	24 (44,5 %)	
Karnofsky (%)		
50-70	31 (57%)	
>70	23 (43%)	
Line of treatment		
1st	29 (54%)	
2nd	14 (26%)	
>2 lines	11 (20%)	
Drug combinations		
bortezomib corticosteroids	26 (39%)	
bortezomib melphalan steroids	16 (24%)	
bortezomib cyclophosphamide steroids	14 (21%)	
bortezomib thalidomide steroids	7 (10%)	
bortezomib lenalidomide steroids	3 (4,5%)	
bortezomib liposomal doxorubicin steroids	1 (1.5%)	
Bortezomib Frequency		
Weekly	32 (54%)	
Twice weekly	27 (46%)	
Bone Marrow Transplantation

Pre-study period	

6 (11%)	
Study period	12 (22%)	
Post-study period	2 (4%)		
None	34 (63%)